PML targeting eradicates quiescent leukaemia-initiating cells

Keisuke Ito, Rosa Bernardi, Alessandro Morotti, Sahoko Matsuoka, Giuseppe Saglio, Yasuo Ikeda, Jacalyn Rosenblatt, David E. Avigan, Julie Teruya-Feldstein and Pier Paolo Pandolfi ()
Additional contact information
Keisuke Ito: Cancer Genetics Program, Beth Israel Deaconess Cancer Center
Rosa Bernardi: Cancer Genetics Program, Beth Israel Deaconess Cancer Center
Alessandro Morotti: Cancer Genetics Program, Beth Israel Deaconess Cancer Center
Sahoko Matsuoka: Keio University School of Medicine, 35 Shinano-machi, Shinjuku-ku, Tokyo 160-8582, Japan
Giuseppe Saglio: University of Turin
Yasuo Ikeda: Keio University School of Medicine, 35 Shinano-machi, Shinjuku-ku, Tokyo 160-8582, Japan
Jacalyn Rosenblatt: Beth Israel Deaconess Medical Center, Harvard Medical School, New Research Building, 330 Brookline Avenue, Boston, Massachusetts 02215, USA
David E. Avigan: Beth Israel Deaconess Medical Center, Harvard Medical School, New Research Building, 330 Brookline Avenue, Boston, Massachusetts 02215, USA
Julie Teruya-Feldstein: Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute, 1275 York Avenue, New York, New York 10021, USA
Pier Paolo Pandolfi: Cancer Genetics Program, Beth Israel Deaconess Cancer Center

Nature, 2008, vol. 453, issue 7198, 1072-1078

Abstract: Abstract The existence of a small population of ‘cancer-initiating cells’ responsible for tumour maintenance has been firmly demonstrated in leukaemia. This concept is currently being tested in solid tumours. Leukaemia-initiating cells, particularly those that are in a quiescent state, are thought to be resistant to chemotherapy and targeted therapies, resulting in disease relapse. Chronic myeloid leukaemia is a paradigmatic haematopoietic stem cell disease in which the leukaemia-initiating-cell pool is not eradicated by current therapy, leading to disease relapse on drug discontinuation. Here we define the critical role of the promyelocytic leukaemia protein (PML) tumour suppressor in haematopoietic stem cell maintenance, and present a new therapeutic approach for targeting quiescent leukaemia-initiating cells and possibly cancer-initiating cells by pharmacological inhibition of PML.

Date: 2008
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/nature07016 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:453:y:2008:i:7198:d:10.1038_nature07016

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature07016

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().